| Recombinant human erythropoietin prevents lipopolysaccharide-induced vascular hyporeactivity in the rat. | |
| | |
MedLine Citation:
|
PMID: 18838949 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Erythropoietin (EPO) is a hypoxia-inducible hormone that is essential for normal erythropoiesis in the bone marrow. Administration of recombinant human-EPO is currently being used for the therapy of anemia associated with chronic renal failure and cancer. Moreover, EPO reduces organ injury in experimental hemorrhagic as well as in splanchnic artery occlusion shock and preserves cardiac function after experimental cardiac I/R. Erythropoietin receptors are widely distributed in the cardiovascular system, including endothelial, smooth muscle, cardiac, and other cell types, and nonhematopoietic effects of EPO are increasingly recognized. Thus, the vasculature may be a biological target of EPO. Therefore, the aim of our study was to investigate whether EPO exerts a protective effect in septic shock by modulating vascular dysfunction and hyporeactivity. Rats received EPO (300 U/kg, i.v.) or vehicle 30 min before and 1 and 3 h after LPS (8 x 10 U/kg, i.v.). In vivo and ex vivo (aortic rings) experiments were performed to evaluate the vascular response to contracting and vasodilating agents. The expression of iNOS, intercellular adhesion molecule 1, poly(ADP)ribose polymerase, Bcl-xl, and Bcl-2 was evaluated by Western blot analysis in the rat aorta. We demonstrate that EPO significantly prevents LPS-induced vascular hyporeactivity and endothelial dysfunction. Interestingly, EPO inhibits the increase in iNOS, poly(ADP)ribose polymerase, and intercellular adhesion molecule 1 expression in the aorta of endotoxemic rats and attenuated the decline in the expression of both Bcl-xl and Bcl-2 caused by LPS. In conclusion, our data support the view that EPO has important nonerythropoietic effects protecting organ and tissue against injury and indicate that EPO may be useful in the therapy of patients with septic shock. |
| | |
Authors:
|
Roberta d'Emmanuele di Villa Bianca; Rosalinda Sorrentino; Emma Mitidieri; Stefania Marzocco; Giuseppina Autore; Christoph Thiemermann; Aldo Pinto; Raffaella Sorrentino |
Related Documents
:
|
21959589 - Interaction of c1 inhibitor with thrombin on the endothelial surface. 7530369 - Lps, recil1 and smooth muscle cell-il1 activate vascular cells by specific mechanisms. 10401559 - Protective effects of a superoxide dismutase mimetic and peroxynitrite decomposition ca... 16338499 - Acceleration of endothelial-like cell differentiation from cd14+ monocytes in vitro. 10753909 - Bacterial lipopolysaccharide activates nf-kappab through toll-like receptor 4 (tlr-4) i... 2416819 - Cultured human vascular endothelial cells acquire adhesiveness for neutrophils after st... 20036889 - Expression of vegf, vegf-c and vegfr-2 in in situ and invasive scc of cervix. 15389489 - Modification of polyurethaneurea with peg and yigsr peptide to enhance endothelializati... 7916369 - Quantitation of icam-1 expression in mouse lung during pneumonia. |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Shock (Augusta, Ga.) Volume: 31 ISSN: 1540-0514 ISO Abbreviation: Shock Publication Date: 2009 May |
Date Detail:
|
Created Date: 2009-04-14 Completed Date: 2009-06-29 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9421564 Medline TA: Shock Country: United States |
Other Details:
|
Languages: eng Pagination: 529-34 Citation Subset: IM |
Affiliation:
|
Dipartimento di Farmacologia Sperimentale, Università degli studi di Napoli, Federico II, Italy. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Acetylcholine
/
pharmacology Animals Blotting, Western Endothelium, Vascular / drug effects, metabolism Erythropoietin, Recombinant / pharmacology* Humans Intercellular Adhesion Molecule-1 / metabolism Lipopolysaccharides / toxicity* Male Nitric Oxide Synthase Type II / metabolism Poly(ADP-ribose) Polymerases / metabolism Proto-Oncogene Proteins c-bcl-2 / metabolism Rats Rats, Wistar Time Factors Vascular Diseases / chemically induced, metabolism, prevention & control* Vasoconstrictor Agents / pharmacology Vasodilator Agents / pharmacology bcl-X Protein / metabolism |
| Chemical | |
Reg. No./Substance:
|
0/Erythropoietin, Recombinant; 0/Lipopolysaccharides; 0/Proto-Oncogene Proteins c-bcl-2; 0/Vasoconstrictor Agents; 0/Vasodilator Agents; 0/bcl-X Protein; 126547-89-5/Intercellular Adhesion Molecule-1; 51-84-3/Acetylcholine; EC 1.14.13.39/Nitric Oxide Synthase Type II; EC 1.14.13.39/Nos2 protein, rat; EC 2.4.2.30/Poly(ADP-ribose) Polymerases |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Urinary liver-type fatty acid-binding protein in septic shock: effect of polymyxin B-immobilized fib...
Next Document: Immunology and epilepsy.